Requiring Clinical Trial Support For Every Sec. 114 Economic Claim “Unwarranted,” PhRMA Tells FDA
Executive Summary
In a recently submitted white paper, PhRMA urges FDA to develop formal regulatory guidance on Sec. 114 of the FDA Modernization Act of 1997, which allows drug companies to proactively disseminate health care economic information to formulary committees.